Clinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens | Zendy

R. R. Kempker | Zendy; Lali Mikiashvili | Zendy; Ying Zhao | Zendy; David Benkeser | Zendy; Ketevan Barbakadze | Zendy; Nino Bablishvili | Zendy; Zaza Avaliani | Zendy; Charles A. Peloquin | Zendy; Henry M. Blumberg | Zendy; Maia Kipiani | Zendy

Open Access

Clinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens

Author(s) -

R. R. Kempker,

Lali Mikiashvili,

Ying Zhao,

David Benkeser,

Ketevan Barbakadze,

Nino Bablishvili,

Zaza Avaliani,

Charles A. Peloquin,

Henry M. Blumberg,

Maia Kipiani

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz1107

Subject(s) - bedaquiline , medicine , sputum culture , regimen , clofazimine , interquartile range , culture conversion , tuberculosis , sputum , adverse effect , mycobacterium tuberculosis , immunology , leprosy , pathology

Bedaquiline and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no comparison studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research